Understanding ALS, commonly referred to as Lou Gehrig's disease
-
By
-
Laura Ungar
-
February 20, 2026
Clinical Scorecard: Understanding ALS, commonly referred to as Lou Gehrig's disease
At a Glance
| Category | Detail |
|---|---|
| Condition | Amyotrophic lateral sclerosis (ALS) is a fatal nervous system disease causing progressive loss of muscle control due to nerve cell death in the brain and spinal cord. |
| Key Mechanisms | Degeneration and death of upper and lower motor neurons leading to muscle paralysis, affecting mobility, speech, swallowing, and breathing. |
| Target Population | Primarily adults aged 40 to 60, slightly more common in men than women. |
| Care Setting | Neurology clinics, specialized ALS centers, and multidisciplinary care involving physical therapy, respiratory support, and palliative care. |
Key Highlights
- ALS causes progressive muscle weakness, twitching, cramps, and eventual paralysis.
- No definitive diagnostic test; diagnosis relies on clinical evaluation, lab tests, and imaging.
- Riluzole is approved to potentially extend survival or delay respiratory support; no cure exists.
Guideline-Based Recommendations
Diagnosis
- Perform thorough physical examination focusing on motor neuron signs.
- Use laboratory tests and imaging of brain and spinal cord to exclude other conditions.
- Identify clinical signs such as muscle twitching, cramps, spasticity, and diminished coordination.
Management
- Prescribe riluzole to potentially extend survival in early disease stages.
- Use symptomatic treatments to manage muscle cramps, spasticity, and respiratory difficulties.
- Implement supportive devices such as braces, wheelchairs, speech synthesizers, and feeding tubes as needed.
Monitoring & Follow-up
- Regularly assess respiratory function and swallowing ability to anticipate complications.
- Monitor progression of muscle weakness and functional status.
- Adjust supportive care and interventions based on symptom evolution.
Risks
- Progressive respiratory failure is the leading cause of death.
- Risk of choking and aspiration due to impaired swallowing.
- Potential complications from immobility and respiratory insufficiency.
Patient & Prescribing Data
Adults diagnosed with ALS, typically aged 40-60 years.
Riluzole may extend survival or delay need for ventilatory support; other medications focus on symptom control; Relyvrio was withdrawn from the U.S. market in 2024.
Clinical Best Practices
- Early recognition of subtle symptoms such as muscle twitching and weakness.
- Comprehensive multidisciplinary care including neurology, respiratory therapy, and nutrition.
- Proactive planning for respiratory support and nutritional interventions.
References
- Centers for Disease Control and Prevention ALS Facts
- Mayo Clinic ALS Overview
- University of California San Francisco Health ALS Information
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
